Voyager Therapeutics (NASDAQ:VYGR) Raised to “Hold” at Wall Street Zen

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Voyager Therapeutics Stock Down 8.6%

Voyager Therapeutics stock opened at $4.45 on Friday. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $5.55. The firm’s fifty day moving average is $3.92 and its 200 day moving average is $4.18. The company has a market capitalization of $265.22 million, a PE ratio of -2.19 and a beta of 1.32.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.08. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. The business had revenue of $13.46 million for the quarter, compared to analyst estimates of $10.49 million. Sell-side analysts expect that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Activity

In related news, CEO Alfred Sandrock sold 14,197 shares of the business’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total value of $53,806.63. Following the completion of the sale, the chief executive officer directly owned 484,060 shares of the company’s stock, valued at $1,834,587.40. The trade was a 2.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 49,783 shares of company stock worth $188,694. 4.53% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VYGR. EcoR1 Capital LLC increased its holdings in shares of Voyager Therapeutics by 497.2% during the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock valued at $15,731,000 after acquiring an additional 3,332,544 shares in the last quarter. Opaleye Management Inc. bought a new position in shares of Voyager Therapeutics in the 4th quarter worth $4,704,000. AQR Capital Management LLC lifted its holdings in shares of Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after purchasing an additional 317,927 shares in the last quarter. Acadian Asset Management LLC grew its position in Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after purchasing an additional 206,758 shares during the period. Finally, Altshuler Shaham Ltd acquired a new stake in Voyager Therapeutics in the 4th quarter valued at $801,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.